20601-85-8

Basic information

• Product Name: Magnolignan
• Synonyms: 2-Hydroxy-2'-hydroxy-5,5'-dipropyl-1,1'-biphenyl;5,5'-Dipropylbiphenyl-2,2'-diol;Magnolignan;Tetrahydromagnolol;Tetrahydromagnolol Exclusive;[1,1'-Biphenyl]-2,2'-diol, 5,5'-dipropyl-
• CAS NO: 20601-85-8
• Molecular Formula: C18H22O2
• Molecular Weight: 270.37
• Mol File: 20601-85-8.mol

Chemical Properties

• Melting Point: 144.5 °C
• Boiling Point: 165.5-166 °C(Press: 2 Torr)
• Appearance: /
• Density: 1.080±0.06 g/cm3(Predicted)
• Solubility: ≤20mg/ml in ethanol;16mg/ml in DMSO;20mg/ml in dimethyl formamide
• PKA: 9.26±0.43(Predicted)
• CAS DataBase Reference: Magnolignan(CAS DataBase Reference)
• NIST Chemistry Reference: Magnolignan(20601-85-8)
• EPA Substance Registry System: Magnolignan(20601-85-8)

Safety Data

• Hazardous Substances Data: 20601-85-8(Hazardous Substances Data)

Usage

Biological Activity

tetrahydromagnolol is a major metabolite of magnolol and acts as a peripheral cb2 receptor agonist. tetrahydromagnolol also acts as an antagonist at gpr55 [1].cannabinoid (cb) receptors belong to the g protein-coupled receptor (gpcr) superfamily and are divided into cb1 and cb2. cb1 activation mediates analgesia, stimulation of appetite, and euphoria, among other effects. cb2 receptor activation results in analgesic and antiinflammatory effects. gpr55, a cb-related orphan receptor, is reported to interact with certain cbs [1].tetrahydromagnolol is a highly selective peripheral cb2 receptor agonist that is 19-fold more potent than magnolol with ec50 and ki values of 0.17 μm and 0.42 μm, respectively. magnolol is a bioactive compound isolated from the bark of magnolia officinalis that is used in asian traditional medicine for the treatment of anxiety, sleeping disorders, and allergic diseases. magnolol behaved as a partial agonist with selectivity for the cb2 subtype (ec50 = 3.28 μm; ki = 1.44 μm). in β-arrestin translocation assay, tetrahydromagnolol inhibited lpi-induced gpr55 activation with kb value of 13.3 μm [1].

references

[1]. rempel v, fuchs a, hinz s, et al. magnolia extract, magnolol, and metabolites: activation of cannabinoid cb2 receptors and blockade of the related gpr55. acs med chem lett. 2012 nov 14;4(1):41-5.

Upstream product

• 528-43-8 Magnolol 
• 87979-85-9 trans-Isomagnolol 
• 860589-82-8 2,2'-dimethoxy-5,5'-dipropyl-biphenyl 
• 64-17-5 ethanol 
• 64-19-7 acetic acid 
• 860734-62-9 2-methoxy-5-propyl-aniline 
• 64080-16-6 2-bromo-4-propylphenol 
• 1413440-39-7 2-hydroxy-5-propylphenylboronic acid 
• 1806-29-7 2,2'-dihydroxybiphenyl 
• 4877-93-4 2,2'-Dimethoxybiphenyl 
• 92310-68-4 4-propylphenyl dimethylcarbamate 
• 28746-11-4 2-nitro-4-propyl-anisole 
• 645-56-7 4-n-Propylphenol 

Relevant articles and documents

Cytotoxic neolignans: An SAR study

The cytotoxic effects of different neolignans with the structure 1 were studied. The neolignans, magnolol 1 and honokiol 2 have been reported to inhibit the growth of several tumor cell lines in vitro and in vivo. The chemical structure of magnolol and honokiol consists of biphenyl skeleton with phenolic and allylic functionalities. Analogs of 1 and 2 containing different substitution have been studies for their effect on the growth of Hep-G2 and their structure-activity relationships were reported in this work.

Design, Synthesis, and Structure-Activity Relationship Studies of Magnolol Derivatives as Antifungal Agents

Plant pathogenic fungi seriously affect agricultural production and are difficult to control. The discovery of new leads based on natural products is an important way to innovate fungicides. In this study, 30 natural-product-based magnolol derivatives wer

Weak Coordination Promoted Regioselective Oxidative Coupling Reaction for 2,2′-Difunctional Biaryl Synthesis in Hexafluoro-2-propanol

An unprecedented weak coordination promoted dehydrogenative cross-coupling reaction has been developed by palladium catalysis, which provides a convenient access to a wide range of 2,2′-difunctional biaryls from easily accessible substrates. Both HFIP solvent and oxidants serve as the critical factors in this new reaction. A plausible mechanism involving Pd(II)/Pd(IV) is proposed. The reaction demonstrates excellent reactivity, broad functional-group tolerance and high yields.

METHOD OF PRODUCING POLYHYDRIC PHENOL COMPOUND

PROBLEM TO BE SOLVED: To provide a method of producing a polyhydric phenol compound which overcomes problems and enables mass production on an industrial scale with high purity at low costs. SOLUTION: A method of producing a polyhydric phenol compound includes a step of obtaining a crude product of a polyhydric phenol from a hydroxy-substituted aromatic compound by an oxidation coupling reaction, a step of dissolving the crude product of the polyhydric phenol in a mixed liquid of a water-soluble organic solvent and water and adding at least one boron-containing compound to the resultant solution and a step of adjusting the pH of the solution to 3.5-7.3, distilling the water-soluble organic solvent away and filtrating the precipitated polyhydric phenol compound separately. COPYRIGHT: (C)2016,JPO&INPIT

PROCESSES FOR MAKING MAGNOLOL ANALOGS

Described herein are high yield methods for making magnolol analogs which are 5,5'-dialkyl-biphenyl-2,2'-diols.

Magnolia extract, magnolol, and metabolites: Activation of cannabinoid CB2 receptors and blockade of the related GPR55

The bark of Magnolia officinalis is used in Asian traditional medicine for the treatment of anxiety, sleeping disorders, and allergic diseases. We found that the extract and its main bioactive constituents, magnolol and honokiol, can activate cannabinoid

Oral compositions containing biphenol antibacterial compounds

Antiplaque oral compositions are provided that contain an orally acceptable carrier and an antibacterial effective amount of the compound of formula (I). In various embodiments, the compositions contain from about 0.001% to about 10% by weight of the compound of formula (I).